ESC in Medical Technology

FDA Submission of B-R-A-H-M-S MR-proANP Kryptor

...stically challenging subgroups such as obesity, higher age or renal dysfunction compared to routinely used markers. First presented at the 2008 esc Congress and subsequently at the 2008 AHA annual meeting, the results of the BACH-trial confirm the company's commitment to improving healthcare throu...

New Data Shows Prescription Omega-3 Acid Ethyl Esters Reduced the Incidence of Death in Heart Failure Patients

... -Data Published in 'The Lancet' and Presented at esc Congress- PHILADELPHIA, Sept. 4 /PRNewswire/ -- Results from a new international study, the GISSI Heart Failure (GISSI-HF) study, showed that 1 g/d ...

Prasugrel Significantly Reduced New or Recurrent Heart Attacks in Both Acute and Longer-Term Settings Following PCI, Compared with Clopidogrel

...5 months) in 13,608 acute coronary syndromes (ACS) patients who were managed with PCI. New or recurrent heart attacks were classified according to the esc Universal Definition of Myocardial Infarction as spontaneous (Type 1) or procedure-related (Type 4 or 5).(1) The analysis showed that prasugrel consis...

Catheter Ablation System for Atrial Fibrillation Shows Reduced Procedure Time, Remarkable Safety Profile and Excellent Outcomes in Two Clinical Studies

...gein, Netherlands at the European Society of Cardiology (ESC) congress. One of the world's most prestigious scientific meetings for cardiologists, the esc meetings took place from August 30 - September 3 in Munich, Germany. Dr. Boersma's first study involved 45 patients with paroxysmal atrial fibrillat...

n-3 PUFAs Reduce Mortality and Hospital Admissions in Patients With Symptomatic Heart Failure

... MUNICH - esc Congress 2008, September 2 /PRNewswire-FirstCall/ -- - Presented at the Annual esc Congress 2008, Munich, Germany, 31 August 2008 F...al practice during a Solvay-sponsored symposium at esc 2008. He commented. "Very recently, we have seen a...

TAXUS OLYMPIA Registry Shows Excellent Outcomes for High-Risk Patients Treated With Second-Generation TAXUS(R) Liberte(R) Stent

... Larry Neumann 508-650-8696 (office) Investor Relations Boston Scientific Corporation On site at esc in Munich Natacha Gassenbach (508) 250-9348 (mobile) Media relations Boston Scientific Gerald...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008

...wledge of PCI use and help inform physicians as to appropriate treatment options for the sickest patients." Details of the Company's activities at esc 2008 are below. Schedule of events (all times are Munich time) Monday, September 1 -- SYNTAX Study data. One-year outcomes data from the SYNTAX t...

Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent

...ing late and very late stent thrombosis out to five years," said Prof. Sigmund Silber, M.D., F.A.C.C., F.E.S.C., who presented the TAXUS II results at esc 2007. "In this trial, the data revealed that the TAXUS paclitaxel-eluting stent maintained its efficacy benefits and had no thrombosis between years f...

Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety

...rik Jorgensen, M.D., from The Heart Centre, University Hospital Rigshospitalet, Copenhagen, Denmark, the investigator who presented the results at the esc Congress. "It is also important to note that at five years, the long-term safety of the CYPHER(R) Stent was comparable to the bare metal stent arm of ...

Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007

...es the data will further reinforce the safety and efficacy of its second-generation drug-eluting stent system. Details of the Company's activities at esc 2007 are below. Schedule of events (all times are Vienna time) Sunday, September 2 -- OLYMPIA Phase II & III one-year data. Preliminary results...

CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007

...eptember 3, CV Therapeutics is sponsoring a FOCUS Cardiology Practice Session, Chronic Stable Angina Management. Additional information regarding the esc Congress 2007 can be accessed at http://www.escardio.org About CV Therapeutics CV Therapeutics, Inc., headquartered in Palo Alto, California, is a...